GleamWall
中文EN

ADMA ADMA BIOLOGICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—

Margins

Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%

Returns

ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$141.10M$124.39M$114.49M$139.16M$134.22M$121.98M$114.80M$117.55M
Cost of revenue$41.19M$38.12M$33.74M$50.35M$58.60M$54.76M$53.70M$54.22M
Gross profit$99.92M$86.28M$80.75M$88.82M$75.63M$67.23M$61.10M$63.33M
R&D expense$4.49M$6.01M$2.60M$1.38M$1.53M$1.03M$826,000$391,000
SG&A expense$26.55M$26.74M$26.74M$23.51M$21.78M$22.21M$24.08M$23.32M
Operating income$67.76M$52.45M$58.27M$62.75M$51.01M$42.80M$34.88M$38.32M
Interest expense$3.43M$3.42M$2.10M$1.63M$1.68M$1.83M$1.98M$2.88M
Pretax income$65.60M$50.24M$57.13M$61.59M$47.52M$40.10M$33.45M$34.71M
Income tax$15.72M$12.41M$11.80M$12.22M$11.09M$5.88M$6.55M-$77.18M
Net income$49.88M$37.82M$45.33M$49.38M$36.43M$34.22M$26.90M$111.90M
EBITDA$69.46M$54.15M$60.07M$64.75M$53.01M$44.80M$36.78M$40.32M
EPS (basic)0.220.170.19—0.150.140.11—
EPS (diluted)0.220.160.19—0.150.140.11—
Weighted avg. shares (diluted)225.82M230.34M239.96M—244.66M248.61M244.68M—
Balance sheet
Cash & equivalents$124.56M$136.02M$138.15M$87.63M$61.38M$90.28M$71.62M$103.15M
Receivables$169.22M$138.23M$135.86M$158.43M$137.67M$109.73M$99.41M$50.00M
Inventory$266.12M$239.31M$222.10M$206.47M$196.67M$191.46M$172.19M$170.24M
Current assets$575.86M$528.20M$511.17M$466.51M$402.65M$399.56M$351.81M$331.41M
PP&E, net$66.76M$66.66M$65.01M$65.06M$69.51M$57.50M$57.71M$54.71M
Goodwill$3.53M$3.53M$3.53M$3.53M$3.53M$3.53M$3.53M$3.53M
Intangibles$581,000$575,000$630,000$632,000$491,000$527,000$452,000$460,000
Total assets$732.49M$684.21M$665.18M$624.24M$568.69M$558.38M$510.57M$488.68M
Current liabilities$95.28M$75.76M$73.54M$69.54M$56.49M$74.94M$53.50M$55.54M
Short-term debt$4.22M$3.75M$3.28M$2.81M$2.34M——$0
Long-term debt$191.64M$192.84M$193.58M$69.33M$70.08M$73.40M$72.53M$72.34M
Total debt$195.86M$196.59M$196.87M$72.14M$72.43M$73.40M$72.53M$72.34M
Total liabilities$293.98M$276.00M$274.86M$146.92M$137.50M$160.06M$137.15M$139.66M
Shareholders' equity$438.51M$408.21M$390.32M$477.32M$431.19M$398.32M$373.42M$349.02M
Net debt$71.30M$60.57M$58.71M-$15.49M$11.04M-$16.89M$902,000-$30.81M
Shares outstanding222.79M225.36M232.29M237.87M238.33M238.57M238.53M236.62M
Cash flow statement
Operating cash flow$17.37M$29.54M$58.25M$35.64M$13.29M$21.14M-$19.68M$50.22M
Capital expenditure$2.00M$2.26M$2.54M$1.08M$14.37M$2.42M$4.70M$2.76M
Free cash flow$15.37M$27.28M$55.71M$34.55M-$1.07M$18.72M-$24.38M$47.46M
Investing cash flow-$2.07M-$2.26M$2.40M-$276,000-$14.37M-$2.53M-$4.72M-$2.75M
Financing cash flow-$26.77M-$29.42M-$10.13M-$9.12M-$27.82M$48,000-$7.13M-$31.03M
Depreciation & amortization$1.70M$1.70M$1.80M$2.00M$2.00M$2.00M$1.90M$2.00M
Stock-based compensation$6.20M$6.13M$6.33M$5.39M$5.05M$4.96M$4.62M$5.43M
Share buybacks$25.05M$25.05M$130.19M$8.90M$23.04M$0$0$0

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.